Drug Trial Radar · NCT07092865
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
168
Actual
Start
Aug 6, 2025
Primary completion
Jan 12, 2027
Study completion Jul 16, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
Adjuvanted RSVPreF3 vaccineBiological
1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- RSV-A neutralizing titers expressed as Geometric mean titers (GMTs)Time frame: At Visit 1 (Day 1) of the current study
- RSV-B neutralizing titers expressed as GMTsTime frame: At Visit 1 (Day 1) of the current study
- RSV-A neutralizing titers expressed as Mean geometric increase (MGI)Time frame: At Visit 1 (Day 1) of the current study over 30 days post last dose in the RSV OA=ADJ-023 study
- RSV-B neutralizing titers expressed as MGITime frame: At Visit 1 (Day 1) of the current study over 30 days post last dose in the RSV OA=ADJ-023 study
- RSV-A neutralizing titers expressed as GMTsTime frame: At Visit 2 (Day 31) of the current study
- RSV-B neutralizing titers expressed as GMTsTime frame: At Visit 2 (Day 31) of the current study
- RSV-A neutralizing titers expressed as GMTsTime frame: At Visit 3 (Day 180) of the current study
- RSV-B neutralizing titers expressed as GMTsTime frame: At Visit 3 (Day 180) of the current study
Locations
38 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
New York, New York
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Temple, Texas
GSK Investigational Site
Camperdown, New South Wales, Australia
GSK Investigational Site
Birtinya, Queensland, Australia
GSK Investigational Site
Herston, Queensland, Australia
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Giessen, Germany
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Palermo, Italy
GSK Investigational Site
Pavia, Italy
GSK Investigational Site
Siena, Italy
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Hyōgo, Japan
GSK Investigational Site
Kumamoto, Japan
GSK Investigational Site
Okayama, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
A Coruña, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Córdoba, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Santander, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.